Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy

Technology appraisal guidance
Reference number: TA1156
Published: 21 May 2026

26769-TSID_10460-Osimertinib-for-Non-Small-Cell-Lung-Cancer-V1.0-NOV2022-NON-CONF.pdf (nihr.ac.uk)

This page was last updated: 23 December 2022